Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Zinc Carnosine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Likely helps
11 of 13 studies with measurable effects showed benefit.
Top outcomes
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
75-150mg daily (providing ~16-34mg zinc)
Between meals on empty stomach, Twice daily for ulcer healing
Zinc L-Carnosine capsules
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
4-8 weeks
4-8 weeks
During use
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis
Frontiers in bioscience (Landmark edition) (2023) · Meta analysis
Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.
Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients (2022) · Meta analysis · n=396
We used the odds ratio (OR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI).
Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data
Nutrients (2020) · Meta analysis
The dose-combined overall polaprezinc increased the change from baseline by a mean of 9.08 µg/dL (95% confidence interval: 5.46, 12.70; heterogeneity: I2 = 0.61%) compared to the placebo.
Based on studies showing 75-77% eradication with zinc carnosine + standard therapy vs 58.6% with standard therapy alone. Limited to 8-week cycles to prevent copper deficiency.
AI-estimated from published studies. Interpret as directional guidance.
Zinc Carnosine has a higher evidence score (6/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Semaglutide and Zinc Carnosine have been documented in our database. However, always consult a healthcare provider before combining supplements.